Skip to main content
Terug
TMDX logo

TransMedics Group, Inc.

Datakwaliteit: 100%
Oversold
TMDX
NASDAQ Healthcare Medical - Devices
€ 108,92
▼ € 3,16 (-2,82%)
Marktkapitalisatie: 3,74B
Dagbereik
€ 108,76 € 112,62
52-Weeksbereik
€ 62,23 € 156,00
Volume
850.344
50D / 200D Gem.
€ 134,33 / € 125,91
Vorige Slotkoers
€ 112,08

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 19,6 0,3
P/B 7,9 2,9
ROE % 54,2 3,7
Net Margin % 31,4 3,8
Rev Growth 5Y % 111,5 10,0
D/E 1,0 0,2

Koersdoel Analisten

Hold
€ 148,17 +36.0%
Low: € 135,00 High: € 166,00
Forward K/W
45,5
Forward WPA
€ 2,46
WPA Groei (sch.)
+0,0%
Omzet Sch.
740 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2029 € 5,81
€ 5,71 – € 5,92
 1,2 B 1
FY2028 € 4,87
€ 4,50 – € 5,46
 1 B 5
FY2027 € 3,67
€ 3,32 – € 4,05
 880 M 8

Belangrijkste Punten

Revenue grew 111,50% annually over 5 years — strong growth
Earnings grew 436,58% over the past year
ROE of 54,24% indicates high profitability
Net margin of 31,43% shows strong profitability
Generating 133,59M in free cash flow
PEG of 0,05 suggests growth is underpriced

Groei

Revenue Growth (5Y)
111,50%
Revenue (1Y)37,13%
Earnings (1Y)436,58%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
54,24%
ROIC8,64%
Net Margin31,43%
Op. Margin17,93%

Veiligheid

Debt / Equity
0,99
Current Ratio7,14
Interest Coverage7,88

Waardering

P/E Ratio
19,63
P/B Ratio7,90
EV/EBITDA34,24
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 37,13% Revenue Growth (3Y) 58,30%
Earnings Growth (1Y) 436,58% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 111,50% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 605,49M Net Income (TTM) 190,29M
ROE 54,24% ROA 17,81%
Gross Margin 59,92% Operating Margin 17,93%
Net Margin 31,43% Free Cash Flow (TTM) 133,59M
ROIC 8,64% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,99 Current Ratio 7,14
Interest Coverage 7,88 Dividend Yield 0,00%
Valuation
P/E Ratio 19,63 P/B Ratio 7,90
P/S Ratio 6,17 PEG Ratio 0,05
EV/EBITDA 34,24 Dividend Yield 0,00%
Market Cap 3,74B Enterprise Value 3,72B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 605,49M 441,54M 241,62M 93,46M 30,26M
Net Income 190,29M 35,46M -25,03M -36,23M -44,22M
EPS (Diluted) 4,87 1,01 -0,77 -1,23 -1,60
Gross Profit 362,81M 262,08M 154,09M 65,27M 21,16M
Operating Income 108,58M 37,50M -28,73M -31,44M -39,43M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,07B 804,08M 706,05M 277,15M 134,89M
Total Liabilities 595,27M 575,47M 568,85M 89,77M 67,04M
Shareholders' Equity 473,10M 228,60M 137,20M 187,38M 67,85M
Total Debt 469,69M 518,29M 515,95M 67,56M 43,80M
Cash & Equivalents 488,37M 336,65M 394,81M 201,18M 25,58M
Current Assets 637,78M 497,22M 510,65M 252,29M 118,71M
Current Liabilities 89,31M 59,91M 54,93M 23,66M 23,24M

Strategiescores

This stock passed the criteria for 4 strategies

Score = fit strength (0–100)
Rank = position among all matches
Growth Growth Investing (Philip Fisher)
#16 of 157
88
Growth + Value Growth at a Reasonable Price (Peter Lynch)
#26 of 332
77
Custom Lower Risk
#33 of 140
54
Custom Full Throttle
#77 of 146
45

Recente Activiteit

Ingestapt Growth Investing (Philip Fisher)
Mar 24, 2026
Ingestapt Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026
Ingestapt Full Throttle
Mar 24, 2026
Ingestapt Lower Risk
Mar 24, 2026